310 related articles for article (PubMed ID: 15677697)
21. Simvastatin inhibits protein isoprenylation in the brain.
Ostrowski SM; Johnson K; Siefert M; Shank S; Sironi L; Wolozin B; Landreth GE; Ziady AG
Neuroscience; 2016 Aug; 329():264-74. PubMed ID: 27180285
[TBL] [Abstract][Full Text] [Related]
22. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes.
Kabouridis PS; Janzen J; Magee AL; Ley SC
Eur J Immunol; 2000 Mar; 30(3):954-63. PubMed ID: 10741414
[TBL] [Abstract][Full Text] [Related]
23. Rho GTPases, statins, and nitric oxide.
Rikitake Y; Liao JK
Circ Res; 2005 Dec; 97(12):1232-5. PubMed ID: 16339495
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering.
Haslinger B; Goedde MF; Toet KH; Kooistra T
Kidney Int; 2002 Nov; 62(5):1611-9. PubMed ID: 12371961
[TBL] [Abstract][Full Text] [Related]
25. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rinaldi B; Capuano A; Matera MG
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):704-10. PubMed ID: 21278325
[TBL] [Abstract][Full Text] [Related]
26. Simvastatin and Ca(2+) signaling in endothelial cells: involvement of rho protein.
Alvarez de Sotomayor M; Andriantsitohaina R
Biochem Biophys Res Commun; 2001 Jan; 280(2):486-90. PubMed ID: 11162544
[TBL] [Abstract][Full Text] [Related]
27. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.
Alizadeh J; Zeki AA; Mirzaei N; Tewary S; Rezaei Moghadam A; Glogowska A; Nagakannan P; Eftekharpour E; Wiechec E; Gordon JW; Xu FY; Field JT; Yoneda KY; Kenyon NJ; Hashemi M; Hatch GM; Hombach-Klonisch S; Klonisch T; Ghavami S
Sci Rep; 2017 Mar; 7():44841. PubMed ID: 28344327
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.
Massonnet B; Normand S; Moschitz R; Delwail A; Favot L; Garcia M; Bourmeyster N; Cuisset L; Grateau G; Morel F; Silvain C; Lecron JC
Eur Cytokine Netw; 2009 Sep; 20(3):112-20. PubMed ID: 19825520
[TBL] [Abstract][Full Text] [Related]
29. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives.
Ghittoni R; Lazzerini PE; Pasini FL; Baldari CT
Inflamm Allergy Drug Targets; 2007 Mar; 6(1):3-16. PubMed ID: 17352684
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease.
Hillyard DZ; Cameron AJ; McDonald KJ; Thomson J; MacIntyre A; Shiels PG; Panarelli M; Jardine AG
Atherosclerosis; 2004 Aug; 175(2):305-13. PubMed ID: 15262187
[TBL] [Abstract][Full Text] [Related]
31. Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells.
Otsuki T; Sakaguchi H; Hatayama T; Fujii T; Tsujioka T; Sugihara T; Takata A; Hyodoh F; Eto M
Oncol Rep; 2004 May; 11(5):1053-8. PubMed ID: 15069546
[TBL] [Abstract][Full Text] [Related]
32. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways.
Chen JC; Huang KC; Lin WW
Cell Signal; 2006 Jan; 18(1):32-9. PubMed ID: 16214041
[TBL] [Abstract][Full Text] [Related]
33. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways.
Nagaoka T; Hein TW; Yoshida A; Kuo L
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):825-32. PubMed ID: 17251484
[TBL] [Abstract][Full Text] [Related]
34. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Martin G; Duez H; Blanquart C; Berezowski V; Poulain P; Fruchart JC; Najib-Fruchart J; Glineur C; Staels B
J Clin Invest; 2001 Jun; 107(11):1423-32. PubMed ID: 11390424
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes.
Araki S; Dobashi K; Asayama K; Shirahata A
Free Radic Res; 2007 Sep; 41(9):1028-34. PubMed ID: 17729120
[TBL] [Abstract][Full Text] [Related]
36. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review).
Fritz G
Int J Oncol; 2005 Nov; 27(5):1401-9. PubMed ID: 16211237
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling.
Miura S; Matsuo Y; Saku K
Atherosclerosis; 2004 Aug; 175(2):235-43. PubMed ID: 15262179
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels.
Turner NA; O'Regan DJ; Ball SG; Porter KE
FASEB J; 2005 May; 19(7):804-6. PubMed ID: 15728660
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
40. Statins Perturb G
Tennakoon M; Kankanamge D; Senarath K; Fasih Z; Karunarathne A
Mol Pharmacol; 2019 Apr; 95(4):361-375. PubMed ID: 30765461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
